- MSS CRC case examples reinforce optimal dosing regimen in ongoing phase 2 dose expansion, with a confirmed partial response at ADG126 10 mg/kg every three weeks plus pembrolizumab – - Integrated ...

Tectonic Therapeutic, Inc., a clinical stage biotechnology company specializing in therapeutic proteins and antibodies that target G-protein coupled receptors (GPCRs), has announced its inclusion in ...

SAN DIEGO and SUZHOU, China, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced data at the ...

Despite the approval of numerous antibody-drug conjugates (ADCs), their therapeutic index remains limited by off-target toxicity resulting from linker instability. To address this challenge, the ...